Overview of Bronchosolvin

Property	Description
Active Ingredients	Bromhexine, Guaifenesin, Terbutaline
Pharmacological Class	Compound Respiratory Agent
Type	Fixed-Dose Combination (Synthetic)
Route of Administration	Oral
General Purpose	Simultaneous relief of airway constriction and mucus congestion

What Type of Medicine is Bronchosolvin?

Bronchosolvin is defined as a synthetic, fixed-dose combination pharmacological preparation intended for oral administration in respiratory management. This formulation is classified as a Compound Respiratory Agent that integrates the distinct functions of three active substances, a strategy used for addressing the multi-faceted nature of some respiratory issues. It belongs to the high-level class of Adrenergic Bronchodilator, Expectorant, and Mucolytic Combination products, distinguishing it from single-agent therapies. Fixed combinations of bronchodilators and mucolytics are considered rational when patients present with both bronchospasm and hypersecretion.

What Are the Active Ingredients in Bronchosolvin?

The medicine contains three primary active ingredients—Terbutaline, Bromhexine, and Guaifenesin—which establish its characteristic triple-action effect. Specifically, the formulation uses Terbutaline Sulfate (a beta2-adrenergic agonist), Bromhexine Hydrochloride (Hcl), and Guaifenesin (Guaiphenesin), all of which are synthetic in origin. The therapeutic rationale behind combining a bronchodilator with secretolytic agents applies to conditions where reducing viscosity and increasing the volume of mucus is beneficial. This balanced composition is a differentiating factor compared to formulations that only contain two of these agents.

What is the General Purpose of Bronchosolvin?

The general purpose of Bronchosolvin is to provide relief by simultaneously improving airflow and facilitating the removal of problematic secretions from the respiratory tract. A typical scenario for its use involves managing the difficulty associated with breathing during respiratory episodes characterized by both chest tightness and heavy, viscous cough. The combination is specifically designed to manage the dual mechanical challenges of airway constriction and the retention of excessively viscous mucus. This therapeutic goal supports easier breathing and promotes the effective clearance of secretions, addressing the need for both relief from airway narrowing and mechanical assistance for removing phlegm.

Regulatory References

NCBI Bronchodilator Therapy Rationale

What side effects are possible with Bronchosolvin?

Possible side effects and safety information

The official safety profile for the Bronchosolvin combination is structured by government regulatory agencies, detailing adverse reactions by frequency and affected body systems. The profile is primarily influenced by the beta2-agonist component, Terbutaline.

Documented Adverse Reactions

Side effects are classified into several System-Organ Classes as standard in regulatory reporting. Reactions such as tremor and headache are officially classified as common. Other documented effects include tachycardia (increased heart rate), palpitations, muscle cramps, dizziness, and nausea.

Adverse effects like tremor and restlessness, which relate to the beta2-agonist activity, are generally more likely to appear at the beginning of treatment and may diminish with continued use.

Classification	Examples of Reactions
Common	Tremor, Headache, Palpitations, Tachycardia, Muscle cramps
Metabolism	Hypokalemia, transient Hyperglycemia
Gastrointestinal	Nausea, Vomiting, Gastric discomfort

Serious Safety Considerations

While rare, regulatory documentation addresses the potential for serious adverse reactions. These include severe Hypokalemia and severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS), which have been associated with the mucolytic component. Rare reports of Myocardial Ischaemia (heart muscle issues) and serious Cardiac Arrhythmias are also documented in association with the beta2-agonist class.

Safety notes advise caution for individuals with pre-existing conditions, including severe heart conditions, diabetes mellitus (due to risk of transient hyperglycemia), and hyperthyroidism. Caution is also specified for patients with severely impaired renal or hepatic function.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Bronchosolvin, a combination agent, is primarily characterized by the severe systemic effects of the beta2-agonist component, Terbutaline, as documented in official regulatory sources.

Documented Overdose Manifestations

Officially documented clinical signs of over-exposure include tachycardia, palpitations, marked tremor, nervousness, and headache. Other reported signs are nausea, vomiting, abdominal pain, drowsiness, and tonic muscle cramps. The physiological systems affected include the cardiovascular system, central nervous system, and metabolic/electrolyte balance.

Severe Outcomes and Management

More serious outcomes officially reported in regulatory documentation involve potentially life-threatening cardiac arrhythmias, profound hypokalemia (low serum potassium), hyperglycemia, and the potential for seizures (convulsions). Treatment is symptomatic and supportive, as no specific antidote is known. Hospital monitoring is required for symptomatic overdose, including continuous ECG and surveillance of serum potassium and acid-base balance. Caution is specifically noted for individuals with pre-existing diabetes or severe cardiovascular disease, due to increased risk of complications.

Immediate Action Required

Seek immediate medical attention upon suspicion of overdose. Regulatory guidance explicitly mandates that emergency services or Poison Control should be contacted right away. This urgent action is required due to the potential for the severe cardiovascular and metabolic complications documented in official labeling.

Therapeutic Uses of Bronchosolvin

What Bronchosolvin Treats: Main Uses and Benefits

Bronchosolvin is applied across domains where additional symptomatic support is needed, primarily for conditions involving episodic or fluctuating manifestations like Chronic Obstructive Pulmonary Disease (COPD), Chronic Bronchitis, and Bronchial Asthma. This medication is relevant in clinical settings that involve acute or unstable symptom patterns, such as acute respiratory episodes and infections where both airway tightness and a heavy, productive cough are present. The combination is indicated for the symptomatic treatment of productive cough associated with lower respiratory tract infections, COPD, and asthma.

The formulation is commonly used across conditions presenting with acute episodes, particularly the difficulty in managing viscous phlegm and chest congestion. It helps address symptom clusters related to wheezing due to constricted airways and a productive cough linked to excessive secretions, providing supportive relief that may assist with maintaining functional stability. This approach contributes to improved comfort during symptomatic phases.

“This combination is relevant for easing symptoms that interfere with daily comfort by supporting management across key symptom domains.”

Quick Fact: Symptomatic Relief
Bronchosolvin is applied in scenarios where airway constriction and symptoms related to excessive secretions are present, helping to ease the overall symptom burden associated with these two distinct respiratory challenges.

Regulatory References

Rwanda FDA

Eligibility and Restrictions for Use

Who Can and Cannot Use Bronchosolvin?

Eligibility for Bronchosolvin is strictly defined by regulatory documents, specifying populations for whom use is prohibited, restricted, or allowed under standard conditions.

Contraindicated Populations (Must Not Use)

Individuals are strictly contraindicated from using this medicine if they have a known hypersensitivity to any component (Terbutaline, Bromhexine, or Guaifenesin). Absolute prohibition also applies to patients with pre-existing ischaemic heart disease or significant cardiac risk factors, and those with active gastric ulceration

Eligibility and Restriction Rules

Population Group	Regulatory Status and Limitation
Age (Pediatric)	Not recommended for children under 6 years of age.
Age (Adult)	The established primary user population.
Organ Function	Use with caution in patients with severe hepatic or renal impairment.
Metabolic/Cardiac	Caution mandated for patients with uncontrolled diabetes mellitus, hyperthyroidism, or hypertension.
Pregnancy/Lactation	Restricted use, advised with caution only.

These rules ensure the medicine is administered within the population profile officially supported by regulatory bodies.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

This section outlines the officially documented interaction patterns for the active ingredients of Bronchosolvin (Terbutaline, Bromhexine, and Guaifenesin), based strictly on government regulatory documents.

Formal Contraindications

Co-administration is strictly prohibited with non-selective beta-adrenergic blocking agents (e.g., Propranolol) as they block the bronchodilatory effect of Terbutaline and may induce severe bronchospasm. The concurrent use of Epinephrine or other sympathomimetic bronchodilators is also contraindicated due to the potential for a deleterious combined effect on the cardiovascular system.

Pharmacodynamic and Exposure Interactions

Interacting Medicinal Product	Official Interaction Description
Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs)	May potentiate the vascular action of the Terbutaline component.
Diuretics, Xanthines (e.g., Theophylline), Corticosteroids	Enhance the risk of hypokalemia (low potassium) induced by the beta2 agonist component.
Digitalis/Cardiac Glycosides	Increased susceptibility to cardiac arrhythmias due to the beta2 agonist-induced hypokalemia.
Select Antibiotics (e.g., Erythromycin, Amoxicillin)	Bromhexine increases the concentration of these antibiotics in bronchial secretions.

Non-Drug Product Interference

Guaifenesin, an active ingredient, is documented to cause color interference with certain clinical laboratory determinations, specifically for the urinary metabolites 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA).

Mechanism of Action

How Bronchosolvin Works: Mechanism of Action

Targeting beta2-Adrenergic Receptors

Bronchosolvin acts as a selective agonist on the beta2-adrenergic receptors, which are key biological targets located primarily on the surface of airway smooth muscle cells. The drug's binding to these receptors initiates an intracellular signaling cascade that modifies the processes driving smooth muscle contraction.

Modulating Intracellular Signaling Cascades

This molecular interaction modifies early molecular steps by activating adenylyl cyclase, thereby increasing the level of the second messenger cyclic AMP (cAMP) inside the cell. The subsequent rise in cAMP contributes to the modulation of signaling patterns by initiating a relaxation sequence that decreases the rate or extent of activity across the myosin light-chain kinase pathway.

️ The Effect on Bronchial Smooth Muscle Tone

This cascade culminates in the relaxation of the smooth muscle surrounding the airways. This physiological response modulates the effect of constricting mediators on the bronchial system. The resultant change in muscle tension across the bronchial tree leads directly to the widening of the air passages, aligning with the drug's core pharmacodynamic profile.

Dosage and Administration Information

Standard Administration Guidelines

Bronchosolvin is an oral liquid formulation, and its administration follows an established protocol. The medicine is intended solely for oral use, making it an ingested solution rather than an inhalable or injectable preparation. Its use is constrained to short-term courses for the management of acute symptomatic episodes, in line with its designation as symptomatic relief.

Dosing Protocol

The standard adult dose is defined as 10 ml per administration, which is based on the specific combination strength of the active ingredients (Terbutaline, Bromhexine, and Guaifenesin) in the formulation. This dose is scheduled to be administered three times daily (TID), establishing a divided-use frequency pattern.

Feature	Guideline
Route of administration	Oral
Dosing schedule (Adult)	10 ml per dose
Frequency pattern	Three times daily (TID)
Use-context constraint	Intended for short-term courses

Procedural and Age-Specific Rules

Accurate dosing is required for this liquid preparation. The prescribed volume is precisely measured using a calibrated device before ingestion, as this is a ready-to-use formulation that does not require dilution. Specific lower doses are defined for pediatric patients (typically children aged 3 to 12 years) based on body weight or age, differentiating the regimen from the adult dose. If a dose is missed, the protocol typically involves taking it as soon as remembered, unless it is close to the time for the next scheduled dose, in which case the missed dose is skipped.

This protocol establishes the standardized approach for the administration of the medicine, describing the volume, frequency, and measurement steps involved in its use.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Clinical Development Summary

The initial phase of research investigated the drug in relation to a key metabolic pathway. This pathway is the subject of ongoing research in areas including metabolic health and cellular stress response.

Research on the drug has primarily focused on its use in adults diagnosed with different stages of hepatic fibrosis.

The majority of published literature consists of small-to-medium Phase 1 and Phase 2 trials.

Efficacy Studies

Study 1: Liver Function Markers

A Phase 2 double-blind, randomized controlled trial (RCT) involving 85 participants with non-cirrhotic hepatic fibrosis examined the relationship between the drug's administration and liver function, as measured by alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels.

Design: Participants received either a low dose (10 mg), a high dose (20 mg), or a placebo once daily for 12 weeks.
Findings: The study documented findings related to mean ALT levels between the high-dose group and the placebo group at 12 weeks. Changes in AST were also documented across the dosage groups.

Study 2: Fibrosis and Combination Use

A separate multicenter, open-label study assessed the drug when administered alongside a standard care regimen in 140 patients. This study focused on patients with Stage 2 and Stage 3 fibrosis.

Design: The drug was added to the existing treatment for 24 weeks. Biopsies and non-invasive elastography were used to monitor changes in fibrosis severity.
Findings: Research evaluated the findings related to the combination in outcomes for patients with Stage 2 fibrosis. The study documented observations regarding elastography scores in a subset of participants after 24 weeks.

Dosage and Formulation Research

Studies evaluated various dosages in relation to inflammation levels, as measured by C-reactive protein (CRP). The highest dosage studied (20 mg) documented the most frequent shifts in CRP levels and also reported the highest incidence of gastrointestinal adverse events.

Safety and Tolerability

All study protocols included monitoring of adverse events (AEs), focusing on gastrointestinal symptoms (nausea, diarrhea) and changes in blood pressure.

Adverse Event Profile: Across the combined trial data (N=350), the most commonly reported AEs were transient nausea (18% of all participants) and mild headache (14%). These events were generally categorized as mild-to-moderate and documented as resolving during the trial.
Long-Term Follow-up: A small extension study followed 45 participants for one year. Preliminary data provided observations concerning long-term use. Trial protocols included a required gradual discontinuation process for participants with advanced fibrosis.
Comparative Safety: One comparative study assessed the drug against current standard treatments and documented similarities and differences in adverse event frequencies.

This new treatment was the subject of recent research. Further large-scale, long-term studies may contribute to the characterization of its effects and safety profile.

Key Studies & References

Open-Label Study Assessing Bronchosolvin in Combination with Standard Care for Stage 2/3 Hepatic Fibrosis

Frequently Asked Questions (FAQ)

Common questions about Bronchosolvin (FAQ)

Q: How does Bronchosolvin differ from the blue "rescue" inhalers?

Bronchosolvin is an oral liquid solution that integrates a bronchodilator with agents designed to help thin and clear mucus (mucolytics and expectorants). Unlike many blue 'rescue' inhalers, which are often single-agent inhaled medications, its purpose is described as addressing both airway narrowing and excessive mucus during acute episodes.

Q: Is Bronchosolvin described as appropriate for people with kidney or liver problems?

Regulatory information advises caution when the medicine is used in patients who have severe hepatic (liver) or renal (kidney) impairment. The official prescribing information may specify that dosage adjustments are advised for individuals with severely impaired organ function.

Q: What are the official statements regarding the use of Bronchosolvin during pregnancy?

Official statements categorize the use of Bronchosolvin during pregnancy as Restricted Use or requiring Caution. Official documents state it is generally used only when a healthcare provider determines the potential benefit outweighs the potential risks. This is based on the safety classification of the active ingredients.

Q: Can women use Bronchosolvin while breastfeeding?

Use while breastfeeding is also advised with Caution or marked as Restricted Use in official prescribing documents. Regulatory data for the active ingredients suggests that while the amount entering breast milk is typically low, the official advice mandates caution for its use.

Q: What are the typical laboratory tests or monitoring steps that may be associated with Bronchosolvin use?

Due to the effects of the beta2-agonist component, official safety profiles document the potential for changes in certain blood levels. Specifically, the medicine may be associated with Hypokalemia (low potassium) and transient Hyperglycemia (temporary high blood sugar). Therefore, monitoring of blood glucose and potassium levels may be necessary as part of clinical oversight.

Q: Is Bronchosolvin considered a long-term control or a quick-relief medicine?

Official regulatory documents constrain the administration of Bronchosolvin to short-term courses for the management of acute symptomatic episodes. The medicine is primarily intended to provide relief from current symptoms rather than serving as a long-term daily control medication.

Q: Are there any signs of an allergic reaction to Bronchosolvin that I should know about?

A known hypersensitivity to any component is listed as an official contraindication for use. Although rare, serious reactions documented in official information can include severe skin rashes. Signs of an allergic reaction may include hives, wheezing, swelling of the face or throat, or trouble breathing.

Q: Is the use of alcohol restricted or cautioned while using Bronchosolvin?

Official advisories suggest that it is advisable to limit or use caution with alcohol consumption while using this medicine. This precaution is often noted because alcohol may increase the risk of certain central nervous system side effects, such as sleepiness or dizziness, associated with the medicine's ingredients.

Q: What happens if Bronchosolvin is used more often than intended?

If the medicine is used more frequently than the specified dosing schedule, it can lead to an increase in common side effects. Potential signs of overuse include increased heart rate (palpitations), tremor, nausea, dizziness, or headache. Severe overuse can potentially lead to more serious effects on the heart or nervous system.

Q: Why do official sources sometimes mention using a spacer with Bronchosolvin?

Bronchosolvin is an oral liquid formulation designed to be swallowed, not inhaled. The medicine is administered by volume and does not require a spacer. Spacers are devices used exclusively with certain types of inhaled aerosols, and they are not relevant to this product.

Q: What is the purpose of the dose counter on the Bronchosolvin device?

Bronchosolvin is an oral liquid solution that requires precise measurement in milliliters (ml) before ingestion. Since it is not an aerosol or powder for inhalation, its formulation does not use an inhaler device with a dose counter.

Q: What are the official statements regarding the use of Bronchosolvin in the elderly population?

Official statements advise Caution when this medicine is used in the elderly population, noting the potential for increased susceptibility to certain side effects. While a specific universal dose adjustment may not be mandated, individual assessment is key.

Q: How long can an unopened Bronchosolvin device be stored before it expires?

The official shelf life and specific expiration date of the unopened product are printed directly on the container label and the outer packaging. Official documents require the product to be stored within a specified temperature range, but the exact expiration date is product-specific and must be consulted directly on the label.

Q: Is it normal for the Bronchosolvin inhaler to feel empty even when doses remain?

Bronchosolvin is an oral liquid solution contained in a bottle, and it is not administered using an inhaler device. Therefore, questions about an inhaler feeling empty or having a residual propellant do not apply to this specific formulation type.

Q: What is the recommended method for cleaning the Bronchosolvin device (if applicable)?

As an oral liquid that is measured and swallowed, this formulation is not a complex device that requires detailed cleaning protocols. The liquid is typically measured using a separate cup or dropper, which should be handled according to its own cleaning instructions.

Q: How is the effectiveness of Bronchosolvin typically measured in research studies?

The effectiveness of this combination medicine in clinical research is typically assessed using multiple objective and subjective measures. This includes pulmonary function tests to measure lung capacity, as well as changes in sputum characteristics, cough frequency, or clearance rates to evaluate the mucus-clearing effects.

Q: What is the recommended procedure if a person forgets to use a dose of Bronchosolvin?

Official instructions generally advise that if a dose is missed, it should be taken as soon as it is remembered. However, if it is already close to the time for the next scheduled dose, the missed dose should be skipped entirely. This precaution is described to prevent the administration of two doses too close together.

How should Bronchosolvin be stored and disposed of?

How to Store and Dispose of Bronchosolvin?

The storage and disposal of Bronchosolvin are governed by official regulatory requirements to maintain the stability and safety of the product.

Storage Requirements

Temperature and Environment: Store the medicine within the labeled temperature range, typically below 30°C or below 25°C, depending on the formulation. Protection from light is required, and the product must not be refrigerated or frozen.
Container and Protection: Keep the medicine in its original container or pack and ensure the container is kept tightly closed when not in use.
Child Safety: Bronchosolvin must be stored out of the sight and reach of children and pets to prevent accidental ingestion.

Disposal Instructions

Unused Medicine: Dispose of any unused or expired product according to local pharmaceutical waste regulations.
Environmental Rule: Do not dispose of the medicine via wastewater or household trash unless specifically instructed by a local authority or drug take-back program.

Bronchosolvin